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The ability to mount a strong immune response against pathogens
is crucial for mammalian survival. However, excessive and un-
controlled immune reactions can lead to autoimmunity. Unravel-
ing how the reactive versus tolerogenic state is controlled might
point toward novel therapeutic strategies to treat autoimmune
diseases. The surface receptor Toso/Faim3 has been linked to
apoptosis, IgM binding, and innate immune responses. In this
study, we used Toso-deficient mice to investigate the importance
of Toso in tolerance and autoimmunity. We found that Toso−/−
mice do not develop severe experimental autoimmune encephalo-
myelitis (EAE), a mouse model for the human disease multiple
sclerosis. Toso−/− dendritic cells were less sensitive to Toll-like re-
ceptor stimulation and induced significantly lower levels of dis-
ease-associated inflammatory T-cell responses. Consistent with
this observation, the transfer of Toso−/− dendritic cells did not in-
duce autoimmune diabetes, indicating their tolerogenic potential.
In Toso−/− mice subjected to EAE induction, we found increased
numbers of regulatory T cells and decreased encephalitogenic cel-
lular infiltrates in the brain. Finally, inhibition of Toso activity in
vivo at either an early or late stage of EAE induction prevented
further disease progression. Taken together, our data identify
Toso as a unique regulator of inflammatory autoimmune responses
and an attractive target for therapeutic intervention.
inflammation | Th1/Th17 cells
More than 5% of the populations of Western countriessuffer from inflammatory autoimmune diseases (1). In all
cases, a hyperactivated immune system is responsible for the
initiation of autoimmunity. In the periphery, inflammatory T
cells such as IL-17–producing Th (Th17) and IFN-γ–producing
Th1 cells are controlled by suppressive regulatory T (Treg) cells
(2). Numeric or functional imbalance of these various T-cell
populations can result in autoimmunity or immunodeficiency.
How the immune system limits self-reactive inflammatory re-
sponses in healthy individuals, and how these mechanisms fail in
patients, is still under intensive investigation.
The transmembrane receptor Toso belongs to the Ig super-
family, and its cytoplasmic domain shows homology to Fas-
activated serine/threonine kinase (3). Toso has been implicated
in the regulation of CD95 (Fas/Apo1)- and TNF receptor
(TNFR)-dependent T-cell apoptosis, and is highly overexpressed
in apoptosis-resistant B-cell lymphomas (3–6). Toso also func-
tions as an Fc receptor for IgM, and so may be important for B-
cell development (7–10). Recently, Toso expression was detected
on granulocytes and monocytes and Toso was linked to the ho-
meostasis and activation of the innate immune system (11–13).
However, the precise physiological relevance of Toso’s multi-
faceted functionality is still unknown.
In this study, we investigated the impact of loss of Toso on
inflammatory autoimmune responses. Toso-deficient (Toso−/−)
mice were less susceptible to the induction of experimental
autoimmune encephalomyelitis (EAE). Disease resistance was
dependent on Toso’s function in dendritic cells (DCs). DCs from
Toso−/− mice initiated less intense inflammatory CD4+ and
CD8+ T-cell responses that were associated with reduced im-
munopathology. Toso−/− DCs induced more Tregs than controls.
Finally, interference with Toso activity in vivo significantly de-
creased the burden of EAE disease following induction. Our
findings indicate that Toso is a crucial mediator of inflammatory
autoimmune responses in vivo.
Results
EAE Is Significantly Reduced in Toso−/− Mice and Is Not Dependent on
T-Cell Differentiation and Function. To clarify the role of Toso in
autoimmune responses in vivo, we investigated whether Toso−/−
mice were susceptible to EAE induction. WT mice developed
severe clinical EAE symptoms. In contrast, EAE disease burden
was significantly reduced by Toso deficiency such that Toso−/−
mice were almost resistant to EAE development (Fig. 1A).
Histological analysis revealed extensive leukocyte infiltration
into the brain cord of WT mice, whereas leukocyte infiltration of
Toso−/− brains was dramatically reduced (Fig. 1B, H&E). In the
central nervous system (CNS) of WT mice, we detected peri-
vascular-centered, diffuse, widespread T-cell infiltrates that were
almost absent in the CNS of Toso−/− mice (Fig. 1B, CD3). The
same pattern was observed for activated macrophages and
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microglia (Fig. 1B, Mac3), which are known to be crucial for EAE
induction (14). However, the inflammatory T-cell infiltration of
the leptomeninges was comparable to WT mice (Fig. S1). Taken
together, these results indicate that Toso plays a key role in
mediating autoimmune inflammation of EAE.
Antigen-specific T-cell expansion and differentiation are hall-
marks of EAE. To evaluate MOG-specific T-cell responses in the
absence of Toso, we isolated splenocytes from EAE-primed WT
and Toso−/− mice and pulsed them with MOG peptide in vitro to
measure proliferation. In contrast to the vigorous expansion of
WT splenocytes, Toso−/− splenocytes showed almost no antigen-
specific proliferation (Fig. 1C), indicating a lack of antigen-
specific cells or a proliferation defect of Toso−/− cells.
EAE development depends on functional CD4+ T cells. Given
our splenocyte data, we speculated that Toso might interfere
directly with T-cell proliferation. To investigate this hypothesis,
we isolated CD4+ T cells from WT and Toso-deficient mice and
measured anti-CD3/CD28–driven expansion in vitro. However,
no difference was detected (Fig. S2A). EAE also depends on naïve
CD4+ T-cell differentiation into the Th17 and Th1 inflammatory
subsets. To assess Toso’s potential role in this process, we isolated
naïve CD4+CD62L+ T cells from WT and Toso−/− mice and in-
duced them to differentiate in vitro into either Th1 or Th17 cells,
as indicated by their secretion of signature cytokines (Th1 cells,
IFN-γ; Th17 cells, IL-17). However, Toso deficiency did not alter
naïve T-cell differentiation into inflammatory Th subsets (Fig.
S2B). We also analyzed CD4+ T cells that were isolated from the
CNS of EAE-primed WT and Toso−/− mice by intracellular flow
cytometry for the expression of IFN-γ and IL-17. The proportion
of IFN-γ–producing T cells in the CNS was slightly lower in MOG-
injected Toso−/− mice than in MOG-injected WT animals, but
there were no differences in the percentage of cells producing IL-
17 alone or IL-17 plus IFN-γ (Fig. S1C). Taken together, Toso has
no impact on Th cell differentiation in vitro or in vivo, and the
EAE resistance observed in Toso−/− mice was not due to an in-
trinsic impairment of Th cell functions.
Toso Modulates DC Activation in Vitro. Based on our results pre-
sented above, we speculated that Toso might be important for
the function of splenic antigen-presenting DCs that are required
to mount and maintain a T-cell response in vivo. To test this, we
incubated WT or Toso−/− bone marrow-derived DCs (BMDCs)
that had been activated with LPS and pulsed with MOG with
either WT or Toso−/− CD4+ 2D2 (MOG-specific) T cells. In
accordance with our earlier results,WT DCs triggered equivalent
levels of antigen-specific proliferation of WT or Toso−/− T cells
(Fig. 2A). However, incubation of Toso−/− DCs with WT or Toso−/−
CD4+ 2D2 T cells led to a drastically reduced proliferative response
Fig. 1. Toso−/− mice develop less severe EAE. (A) WT (n = 17) and Toso−/−
(n = 17) mice were subjected to EAE. Data are the mean score ± SEM and are
combined from four independent experiments. (B) Representative histo-
pathological analyses of cross-sections of CNS from the mice in A at 20 d
post-MOG injection. CNS sections were stained with H&E or immunostained
to detect CD3+ T cells and macrophages (Mac3). Data are from one mouse
per group. (Scale bar, 100 μm.) (C) Splenocytes isolated from WT and Toso−/−
mice were pulsed with the indicated concentrations of MOG peptide. Cells
were cultured for 72 h and pulsed for the last 8 h with [3H]thymidine. Data
are the mean ± SEM of three biological replicates and are representative of
two independent experiments.
Fig. 2. Toso modulates DC activation and function. (A) Toso−/− and WT BMDCs
(3 × 104) were activated for 16 h with LPS and pulsed with MOG peptide (light
gray; dark gray: nonpulsed). MOG-loaded Toso−/− and WT BMDCs were in-
cubated with VCT-labeled Toso−/− or WT 2D2 CD4+ T cells (1 × 105). Proliferation
was measured 72 h later by flow cytometry. (B) Toso−/− and WT BMDCs were
activated for 16 h with the indicated TLR ligands and assessed for their expres-
sion of CD80, CD86, and MHCII. WT BMDCs, lower dark line; Toso−/− BMDCs,
upper light line. Data are gated on live CD4+ T cells (A) or on live CD11c+ cells (B)
and are representative of five independent experiments.









in both cases. These results indicate that Toso is critical for
mounting a DC-dependent T-cell response.
Upon activation, immature DCs begin to mature and up-reg-
ulate costimulatory molecules important for T-cell priming. To
examine whether Toso plays a role in this process, we stimulated
WT and Toso−/− BMDCs with various Toll-like receptor (TLR)
ligands, including LPS, R848, and CpG, and monitored surface
up-regulation of CD80, CD86, and MHCII by flow cytometry.
Interestingly, even before TLR ligand stimulation, Toso−/− im-
mature DCs exhibited lower surface levels of CD80, CD86, and
MHCII (Fig. 2B). These levels were further reduced upon TLR
ligation by LPS, R848, or CpG (Fig. 2B), implying that DC
stimulation in the absence of Toso may block DC maturation
and render these cells tolerogenic.
Toso-Deficient DCs Do Not Induce Inflammation in Vivo. In addition
to their important role in initiating immune responses against
foreign antigens, DCs are central regulators of peripheral tol-
erance to self-antigens (15). Tolerogenic DCs are characterized
by their decreased potential to stimulate inflammatory T-cell
responses and their low surface levels of CD80, CD86, and
MHCII (15–17). To investigate whether Toso−/− DCs can mount
an autoimmune T-cell response in vivo, we took advantage of the
RIP-GP mouse model (18). RIP-GP mice express the GP anti-
gen on their pancreatic islet cells. Upon transfer of CpG-acti-
vated antigen-pulsed WT BMDCs into RIP-GP mice, GP-
expressing pancreatic islet cells are attacked by GP-specific T
cells. This immune response results in islet cell depletion, in-
duction of diabetes, and subsequent death of the mice (19). We
transferred WT or Toso−/− BMDCs into RIP-GP mice and mon-
itored mouse survival and damage to pancreatic islets. Whereas
almost all control animals receiving WT BMDCs became hyper-
glycemic and reached the humane end point, not a single animal
that had received Toso−/− BMDCs displayed hyperglycemia (Fig.
3A). Histological analysis of the pancreas revealed abundant T-
cell infiltrates in RIP-GP mice that had received WT BMDCs
(Fig. 3B). Although T-cell infiltrates were also obvious in mice
that had received Toso−/− BMDCs, this infiltration was far less
pronounced and correlated with the lower blood glucose levels
observed in these animals (Fig. 3C). Taken together, these
results show that Toso−/− DCs cannot mount disease-initiating
inflammatory effector T-cell responses, and indicate that Toso
might play an important role in regulating the inflammatory vs.
the tolerogenic state of DCs.
Toso−/− DCs Preferentially Induce Tregs in Vitro and in Vivo. To
further examine our hypothesis that Toso−/− DCs attenuate in-
flammatory T-cell responses, we cultured MOG antigen-pulsed
WT or Toso−/− BMDCs with WT 2D2 CD4+ T cells and deter-
mined surface expression levels of the T-cell activation markers
CD25, CD44, and ICOS by flow cytometry. Up-regulation of
CD25, CD44, and ICOS on MOG-stimulated WT CD4+ 2D2 T
cells was lower when these T cells were stimulated by Toso−/−
DCs compared with WT DCs (Fig. 4A). Interestingly, we found
a significantly higher proportion of FoxP3-expressing Treg cells
among CD4+CD25+ T cells in cultures exposed to Toso−/−
BMDCs compared with their numbers in cultures exposed to
WT BMDCs (Fig. 4B). This could be further enhanced by ad-
dition of TGF-β (Treg skewing condition) to the DC/T-cell cul-
ture (Fig. S3A). These findings suggested that Toso−/− DCs are
weak inducers of inflammatory T-cell responses but strong in-
ducers of Tregs. In addition, Toso−/− DCs expressed more PD-L1
on their cell surfaces compared with controls (Fig. 4C). PD-L1
has been shown to induce FoxP3 expression in T cells (20), po-
tentially explaining the increased Treg numbers in cultures of T
cells exposed to Toso−/− DCs. Interestingly, T-cell intrinsic dif-
ferentiation to Tregs and also their suppressive capacity showed
no differences between WT and Toso−/− genotypes (Fig. S3 B
and C). Considering this, we conclude that Toso does not reg-
ulate Treg functionality but rather Treg numbers. Further on,
regulation of Treg numbers is not a T-cell intrinsic effect but is
mediated by Toso−/− DCs.
To validate our hypothesis in vivo, we first characterized T-cell
maturation of Toso−/− mice in the thymus. As expected, CD4+ and
CD8+ T-cell compartments were not altered by Toso deficiency
(Fig. S4). Within the CD4+ T cells, we found a similar amount of
naturally occurring FoxP3+ Tregs (nTregs). To see whether these
Treg proportions change during inflammatory conditions, we in-
duced EAE in WT and Toso−/− mice by injecting MOG-peptide
emulsion and killed the mice 14 d later. Consistent with our in vitro
findings, we observed in vivo an increase in CD4+CD25+FoxP3+-
expressing cells of our MOG-injected Toso−/− mice compared with
MOG-injected WT animals (Fig. 4D). In line with this, quantifi-
cation of CD4+ cells confirmed that overall CNS infiltration in
MOG-injected Toso−/− mice was significantly lower than in controls
(Fig. 4E). Taken together, we conclude that Toso deficiency shifts
the balance from an inflammatory to a tolerogenic T-cell response
and decreases the overall abundance of inflammatory cells in the
brain. Toso is crucial for the proinflammatory function of DCs and
suppresses Treg cell induction during EAE.
Fig. 3. Toso−/− DCs are unable to induce diabetes in RIP-GP mice. Activated
antigen-pulsed DCs were transferred into RIP-GP mice (n = 10 per group). (A)
Kaplan–Meier analysis of mouse survival over a 30-d observation period. *P ≤
0.05. (B) Histological cross-sections of the pancreas were taken on day 8 and
immunostained to detect CD3+ T cells (brown infiltrates, CD3 staining). Results
are representative of five pancreatic sections per group. (Scale bar, 100 μm.)
(C) Blood glucose levels were determined every other day. Data are the mean
score ± SEM (n = 10).
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Blocking of Toso Action Interferes with EAE Development at Multiple
Stages of the Disease. The blocking of signaling pathways by re-
ceptor-Fc fusion proteins has proven to be a powerful tool for
manipulating disease-associated immune responses (21). For
example, Etanercept is a fusion protein in which the TNF re-
ceptor is linked to the Fc portion of an IgG1 antibody. Eta-
nercept acts as a decoy receptor that binds TNF (22), and so has
been used therapeutically to treat human inflammatory auto-
immune diseases such as rheumatoid arthritis (23). To translate
our knowledge of the importance of Toso in inflammatory
responses into a preclinical treatment application, we generated
a Toso-Fc fusion protein consisting of the human Toso extra-
cellular domain fused to the Fc portion of an IgG1 antibody that
harbors a series of mutations preventing the activation of the
complement system (SI Materials and Methods). We hypothesized
that treatment ofWTmice with this Toso-Fc fusion protein (Toso-
Fc) might protect against EAE. We induced EAE, and treated
these animals with Toso-Fc either during the disease-priming
phase (days 0–8) or during the effector phase (days 10–18).
Strikingly, treatment with Toso-Fc dramatically reduced disease
severity and slowed disease progression in both cases. Mice that
were injected every other day with Toso-Fc during the priming
phase developed only a mild form of EAE, and the disease did not
progress significantly after the treatment was stopped on day 8
(Fig. 5). Importantly, mice that already showed symptoms of EAE
before Toso-Fc injection on day 10 also responded to the treat-
ment in that disease progression was prevented (Fig. 5). Thus, we
are confident that Toso-Fc treatment at any stage of EAE de-
velopment can slow disease progression. This important result
shows great promise for the therapeutic potential of our findings,
and highlights the key role of Toso in inflammatory diseases.
Discussion
Currently, the treatment of inflammatory autoimmune diseases
is a major medical challenge. Multiple sclerosis (MS) is espe-
cially worrying because of its prevalence in young adults. For this
group, MS is the most common cause of a nonreversible dis-
ability, as well as a severe social and occupational health problem
(24). Effective treatment of autoimmune diseases requires know-
ledge of how they develop, the subject of much ongoing debate. In
this study, we provide evidence that the transmembrane receptor
Toso is crucial for the development of EAE, a mouse model of MS.
Our in vivo findings demonstrate that Toso−/− mice are less
susceptible to EAE induction and show lower levels of in-
flammatory cell infiltrates in the CNS. Although Th17 cells are
considered the main drivers of EAE (25–27), mice in which Th1
cell responses are impaired do show EAE resistance, supporting
the theory that both inflammatory Th subsets are needed to in-
duce the disease (28). In our study, we could not detect any in-
fluence of Toso on the differentiation of Th1 or Th17 cells in
vitro or in vivo. Several groups have reported that functional
Th17 cells are important for the recruitment of inflammatory
macrophages to the CNS that sustain neuroinflammation (25, 29,
30). Although we found a reduced degree of macrophage in-
filtration into the CNS in sections of Toso-deficient brains, our in
vitro work established that it is not the T-cell compartment but
rather antigen-presenting DCs that are responsible for the re-
duced EAE disease burden in Toso−/− mice. When Toso−/− DCs
were incubated in vitro with MOG-specific WT T cells, much
weaker T-cell proliferation and costimulatory molecule expres-
sion were observed than when WT DCs were used to present
MOG. Phenotypically, Toso−/− DCs retain a more immature
state, with lower levels of MHCII, CD80, and CD86 expression
compared with mature inflammatory DCs (31). These results
suggest that Toso plays a critical driving role in the DCs that
underpin autoimmune inflammation. This hypothesis was con-
firmed by our DC transfer experiments in RIP-GP mice (19).
Toso−/− DCs were unable to induce diabetes, but did not com-
pletely abrogate T-cell activation. However, T-cell infiltration
into the pancreas was reduced compared with mice that received
WT DCs. These data strongly support a role for Toso in regu-
lating the proinflammatory capacity of DCs.
Several studies have linked immature DCs to tolerance in-
duction (15, 17, 31–33), and an interesting recent report has
shown that the main physiological function of WT DCs during
EAE induction is to induce naïve T cells to differentiate into
Fig. 4. Toso deficiency in DCs increases Treg induction in vitro and in vivo.
(A–C) BMDCs from WT or Toso−/− mice were activated with LPS and cocul-
tured with naïve CD62LhighCD4+ T cells as described in Fig. 2. (A) Flow
cytometric determination of T-cell expression levels of CD25, CD44, and
ICOS. T cells stimulated with WT DCs, tinted line; T cells stimulated with
Toso−/− DCs, dark line. Data are representative of three independent
experiments. (B) FoxP3 expression by the CD25+CD62LhighCD4+ T-cell sub-
populations in A. Data are the mean ± SEM (n = 5). (C) Flow cytometric
determination of PD-L1 expression by the DCs in A. Data are the mean ± SEM
(n = 5). For A–C, data were acquired by gating on live CD4+ T cells (A and B)
or on live CD11c+ cells (C). (D and E) WT and Toso−/− mice (n = 5 per group)
were subjected to EAE induction and killed on day 14 postinduction. Samples
of CNS were subjected to gradient centrifugation to isolate CNS-infiltrating
leukocytes. (D) Percentage of peripheral CD4+ T cells expressing FoxP3 and
CD25. (E) Total numbers of CNS-infiltrating cells in WT and Toso−/− mice. For
D and E, data are mean ± SEM (n = 5 per group; *P < 0.05).
Fig. 5. Soluble Toso-Fc fusion protein blocks EAE disease progression. EAE
was induced in WT mice that were then injected every other day with either
50 μg Toso-Fc fusion protein or PBS (control) (n = 4 per group). Toso-Fc was
administered either between days 0 and 8 (Toso-Fc d0-8) or between days 10
and 18 (Toso-Fc d10-18). Disease severity was scored daily. Data are the mean
score ± SEM and are representative of two independent experiments.









Tregs (34). Accordingly, depletion of WT DCs in this model did
not ameliorate EAE but instead exacerbated disease progression
due to Treg deficiency (34). These results implied that although
WTDCs can still prime inflammatory T cells, their main function
is to induce Tregs and thereby control the balance between in-
flammation and tolerance. In this light, it will be interesting to
define the molecules that regulate the tolerogenic function of
WT DCs. In our study, we characterized Toso as a proinflam-
matory protein, and showed that loss of Toso induces a tolero-
genic phenotype in DCs. Toso−/− DCs can both restrain the
expansion of inflammatory T cells and induce Tregs in vitro and in
vivo during EAE induction. Toso had no influence on the T-cell
intrinsic differentiation process to Tregs, nor did Toso-deficient
Tregs exhibit an altered activity compared with controls. We
suggest that Treg induction in Toso−/− mice during EAE is solely
dependent on DCs. We also demonstrated that Toso−/− DCs ex-
press increased amounts of PD-L1 on the cell surface compared
with WT DCs. PD-L1 interactions have been shown to suppress
autoreactive T cells, and are implicated in the induction of FoxP3-
expressing induced Tregs (iTregs) (20, 35, 36). The up-regulation
of PD-L1 on Toso−/− DCs might explain the higher numbers of
iTregs found in Toso−/− mice upon EAE induction. Interestingly,
the numbers of nTregs were not altered by Toso deficiency, which
implies that Toso just restrains iTregs in response to an
inflammatory stimulus.
Based on our finding that Toso has a crucial function in im-
mune tolerance, we developed a preclinical strategy for treating
autoimmune disease. Our recombinant Toso-Fc fusion protein
successfully interfered with EAE induction in mice. Most im-
portantly, Toso-Fc stopped disease progression in animals that
were already symptomatic. Treatment strategies based on re-
ceptor-Fc fusion proteins have proven to be powerful alternatives
to immunosuppressive drugs in the clinic (21). Conceptually,
a therapeutic receptor-Fc fusion protein competes with the in-
flammatory receptor for binding to the natural ligand, preventing
the initiation of inflammatory signaling. The success of this ap-
proach depends on creating a receptor-Fc fusion protein that has
high affinity for the natural ligand and can accumulate to high
concentrations in a patient’s blood. Several therapeutic receptor-
Fc fusion proteins, including Etanercept (TNFR-Fc), Alefacept
(LFA3-Fc), Rilonacept (IL1R-Fc), and Abatacept (CTLA4-Fc),
are on the market, and many more have entered clinical trials (22,
37–39). Around the globe, patients suffering from inflammatory
autoimmune diseases such as MS, rheumatoid arthritis, psoriasis,
and gout have benefited significantly from therapeutics based on
receptor-Fc fusion proteins. Our preclinical experiments with our
Toso-Fc fusion protein are only the first step in the development
of a such targeted therapeutic. Many open questions remain, not
the least of which is the nature of the Toso ligand. Future studies
will be needed to unravel the molecular mechanism underlying
Toso’s function in the inflammation–tolerance balance. It is also
evident that, based on Toso’s diverse roles, the generation of
conditional Toso-deficient mutants will be an asset.
In summary, we have demonstrated that Toso has an impor-
tant proinflammatory function that is rooted in its effects on
DCs. Toso−/− mice show a significantly decreased EAE disease
burden, and Toso−/− DCs are tolerogenic and weak stimulators
of inflammatory T-cell responses. Importantly, we have de-
veloped an effective preclinical treatment strategy that reduced
EAE disease progression in mice. Our results set the stage for
potential therapeutic strategies aimed at mitigating autoimmune
inflammation in humans.
Materials and Methods
Mice. Toso−/− and RIP-GP mice, as well as P14 transgenic strains, were bred in-
house and were described earlier (12, 19, 40). 2D2 and C57/BL6 mice were
from The Jackson Laboratory.
EAE Induction. Mice were s.c. immunized with MOG 35–55 peptide, and
clinical signs of EAE were monitored daily as described previously (41). For
treatment with Toso-Fc fusion protein during EAE induction, mice were
treated i.p. with 50 μg Toso-Fc (additional information is available in SI
Materials and Methods) or PBS (vehicle control) every other day.
Histology and Immunohistochemistry. Brains were obtained from mice at 30 d
post-MOG injection. Brains and pancreas were fixed, processed, and stained
as previously described (41). For immunohistochemical staining, the follow-
ing antibodies and dilutions were used: anti-CD3 (Dako; 1:200) and anti-
Mac3 (BD Pharmingen; 1:100).
Lymphocyte Isolation and CD4+ T-Helper Cell Purification and Differentiation.
Lymphocytes from brain tissue and Th cells from spleen and lymph nodes
were isolated according to standard protocols. Naïve CD4+CD26Lhigh T cells
were purified and induced to differentiate into Th1, Th17, or Treg cells with
subset-specific cytokine mixtures as described previously (41).
For DC-dependent Treg skewing experiments, DCs were pulsed for 3 hwith
1 μg/mL lymphocytic choriomeningitis virus (LCMV) peptide gp61–80
(GLNGPDIYKGVYQFKSVEFD), washed twice with PBS, and cocultured with
WT CD4+ Smarta T cells (10 T-cells:1 DC) in the presence of TGF-β (10 ng/mL),
IL-2 (10 ng/mL), and anti–IFN-γ Ab (10 μg/mL) (BioLegend). Cells were stained
72 h later for CD4 and FoxP3 using the FoxP3 Staining Buffer Set (eBio-
science) and analyzed using a Canto II (BD Biosciences).
Cell-Proliferation Assay. Whole spleens were homogenized to generate sin-
gle-cell suspensions, and erythrocytes were lysed using a red blood cell lysis
buffer (Sigma). Splenocytes were washed in PBS, resuspended at a concen-
tration of 1 × 106 cells per mL, and pulsed with 0.1–100 μg/mL MOG peptide.
CD4+ T cells were purified by standard protocols and stimulated with plate-
bound anti-CD3 antibodies at the indicated concentration. Splenocytes or T
cells were incubated for 48 h and pulsed for the last 8 h with [3H]thymidine
(1 μCi per well). Incorporation of [3H]thymidine was measured with a Matrix
96 Direct β Counter System (Canberra Packard).
Cytokine Production. Cytokines were analyzed by intracellular staining. T cells
were isolated directly frommouse brain, spinal cord, or spleen or harvested after
culture in vitro. Cellswereanalyzedby flowcytometry as describedpreviously (41).
BMDC Differentiation, Antigen-Specific Proliferation, and Treg Suppression
Assay. DCs were induced to differentiate from bone marrow stem cells by
culture for 10 d in RPMI containing 40 ng/mL GM-CSF (PeproTech). On day
10, cells were harvested, washed twice in PBS, and stimulated for 16 h with
10 ng/mL LPS (Sigma), 10 ng/mL R848, or 10 nM CpG. DCs were then stained as
described above or pulsed for 3 h with 1 μMMOG peptide, washed twice with
PBS, and cocultured with WT CD4+ 2D2 T cells that had been labeled with
2.5 μM CellTrace Violet (VCT) (Invitrogen) according to the manufacturer’s
instructions. Proliferation was measured 72 h later using a Canto II plate
reader (BD Biosciences) and analyzed using FlowJo 7.5 software (Tree Star).
For Treg suppression assays, we used 1 × 104 activated and MOG-pulsed WT
BMDCs. In vitro differentiated iTregs (1 × 105) were coincubated with 1 × 105
VCT-labeled 2D2 CD4+ T cells. Proliferation was analyzed after 72 h by
flow cytometry.
Surface Marker Staining. BMDCs were cultured alone or in combination with
T cells as described above. Cells were stained by standard protocols with
the following antibodies (BioLegend): anti-CD25, anti-CD4, anti-MHCII, anti-
CD80, anti-CD86, anti-ICOS, and anti–PD-L1.
BMDC Transfer into RIP-GP Mice. BMDCs were generated as described above,
activated with 10 ng/mL LPS for 20 h, and pulsed for 16 h with 1 μM GP33,
GP276, and GP61 peptides. Two million cells were i.v. injected per RIP-GP
mouse. Blood glucose levels were determined every other day in tail blood
using Accu-Chek III glucometers and Chemstrips (Roche).
Statistical Methods. Where appropriate, all differences were evaluated using
the two-tailed Student t test as calculated using Prism 5.0 software (GraphPad).
Data are presented as the mean ± SEM. Differences with P values ≤0.05 were
considered significant.
Study Approval. All mouse procedures were approved by the University
Health Network Institutional Animal Care and Use Committee.
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